Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | G1T48 |
| Synonyms | |
| Therapy Description |
G1T48 is an orally bioavailable selective inhibitor of estrogen receptor (ER) that leads to down-regulation of ER and growth inhibition of ER-positive tumor cells (PMID: 32130619). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| G1T48 | G1T48 is an orally bioavailable selective inhibitor of estrogen receptor (ER) that leads to down-regulation of ER and growth inhibition of ER-positive tumor cells (PMID: 32130619). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03455270 | Phase I | G1T48 G1T48 + Palbociclib | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | Completed | USA | NLD | BGR | BEL | 3 |